

OCTOBER 16-19, 2024  
CHICAGO, ILLINOIS



# Chicago Specials

## Fall Group Meeting

Melanoma Committee

# Melanoma Committee

## Leadership

Chair: ..... Sapna P. Patel, MD  
 Vice-Chair: ..... Roger S. Lo, MD, PhD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Michael Wu, PhD  
 ..... Megan Othus, PhD  
 ..... James Moon, MS  
 ..... Hongli Li, MS  
 ..... Allison Hayes, BS

## Scientific Leadership

Translational Medicine: ..... William E. Carson, III, MD  
 Radiation Oncology: ..... Evan J. Wuthrick, MD  
 Surgery: ..... John Robert Hyngstrom, MD  
 Dermatology: ..... Clara Curiel-Lewandrowski, MD  
 Imaging: ..... Ari M. VanderWalde, MD  
 Medical Oncology: ..... Sapna Pradyuman Patel, MD  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Nikhil I. Khushalani, MD  
 Early Therapeutics: ..... Jeffrey A. Sosman, MD  
 SWOG's ECOG Liaisons: ..... Thach-Giao Truong, MD  
 ECOG's SWOG Liaisons: ..... David H. Lawson, MD  
 ..... Andrew Poklepovic, MD  
 Digital Engagement: ..... Zeynep Eroglu, MD

## Designates

Cancer Control Liaison: ..... Sancy Leachman, MD, PhD  
 ..... Thach-Giao Truong, MD (Survivorship)  
 Data Coordinator: ..... Cassie Villasin, BA  
 ..... Michele Counts, BS  
 ..... Tonya Johnson, BS  
 Oncology Research Professionals:  
 CRA: ..... Kathryn Allen, BA, CCRP  
 Nurse: ..... TBD  
 Patient Advocate: ..... Samantha Guild, J.D.  
 Pharmaceutical Science: ..... Sun "Coco" Yang, PharmD, PhD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Friday, October 18, 2024 2:15 p.m. - 4:15 p.m.  
 Room: Crystal C (Lobby Level, West Tower)

## Keynote Speaker

Translational approaches to melanoma: perspectives of a surgeon  
 Genevieve Boland, MD, PhD, Vice Chair of Research, Harvard Medical School, Massachusetts General Hospital

## Presentation

SWOG S1616: Translational insights stratifying primary resistance to Anti-PD-1 in melanoma - Katie Campbell, PhD

## Active Studies

**S2015**, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 4/8/22.

**CTSU/EA6174**, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/1/18. Temporarily Closed to Accrual as of 4/7/23

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 9/10/15.

**CTSU/EA6192**, "The BMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/20.

**A091903**, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma." SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/23

## Studies in Development

**S2431**, "Randomized, open-label, phase III study of anti-PD-1, anti-CTLA-4, and anti-LAG-3 antibodies in patients with previously untreated unresectable or metastatic melanoma". Dr. Chandra

## Closed Studies

**S2000**, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 9/23/20. Closed: 6/18/24



# Melanoma Committee

**S1801**, “A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma.” Dr. Patel. Activated: 12/6/18. Closed: 5/5/22.

**S1512**, “A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM).” Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 6/4/21.

**S1607**, “A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy.” Dr. Hu-Lieskovan. Activated: 10/2/17. Closed: 11/1/20.

**S1616**, “A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 7/17/17. Closed: 7/15/20.

**S1404**, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/15. Closed: 11/2/17.

**CTSU/EA6134**, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/21.

**CTSU/EA6183**, “A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D).” SWOG Champion: C. D. Lao, MD, MPh Activated: 2/18/20. Closed: 9/23/22.

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

## Published/Accepted Manuscripts

**S0826** SWOG S0826: A phase II trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Ma V, Moon J, Fruehauf J, Flaherty L, Bury M, Martin W, Gross H, Akerley W, Hopkins J, Patel S, Sondak V, Ribas A. Accepted 2024.

## Submitted Manuscripts

**S1801** Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. Submitted 2024.

## Melanoma Committee

**Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study**

	S2000	A091903	EA6141	EA6174	EA6192	EA6194	S2015
Banner MD Anderson Cancer Center	-	-	-	-	-	-	13
Banner University Medical Center - Tucson	-	-	-	3	-	1	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	16	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	74
Cancer Research for the Ozarks NCORP	1	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	17
City of Hope Comprehensive Cancer Center	-	-	3	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	1
Dayton NCI Community Oncology Research Program	1	-	2	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	10
Fred Hutchinson Cancer Research Center LAPS	-	-	-	1	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	7
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	7
Intermountain Medical Center	-	-	-	-	-	-	19
Kaiser Permanente NCI Community Oncology Research Program	-	-	26	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	12
Moffitt Cancer Center	20	-	-	-	-	-	46
Nevada Cancer Research Foundation NCORP	-	-	-	1	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	2
Northwell Health NCORP	-	-	-	-	-	-	6
Northwestern University LAPS	-	-	1	1	5	-	28
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	3	3	-	24
SCL Health Saint Joseph Hospital	-	-	-	1	-	-	-
Sutter Cancer Research Consortium	-	-	7	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	4	8	-	3	8
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	1	-	3	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	-	5
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	4	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	1	1	-	-	41
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	4
University of Michigan Comprehensive Cancer Center LAPS	2	-	-	-	-	-	12
University of Nebraska Medical Center	-	-	-	-	-	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	1
University of Rochester LAPS	-	-	4	1	-	-	5
University of Texas Health Science Center at San Antonio	-	-	1	-	-	-	3
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	15
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	8	-	-	25
Western States Cancer Research NCORP	-	-	1	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	10
Yale University - Yale Cancer Center LAPS	-	-	8	1	-	-	21
ALLIANCE	1	-	-	-	-	-	59
ECOG-ACRIN	6	-	-	-	-	-	146
NRG	1	-	-	-	-	-	66
<b>Total</b>	<b>37</b>	<b>1</b>	<b>61</b>	<b>53</b>	<b>9</b>	<b>4</b>	<b>690</b>

